自体人源化PDX平台评估卵巢癌免疫治疗
研究将三例高级别浆液性卵巢癌患者的自体肿瘤浸润淋巴细胞(TIL)转移至患者匹配的PDX模型,建立人源化平台。TIL与自体肿瘤共培养显示HLA依赖性IFNγ产生和T细胞活化增加,并上调肿瘤PD-L1;抗PD-1抗体在CCNE1扩增模型中增加自体肿瘤溶解。在PDX模型中,自体肿瘤反应性TIL联合抗PD-1治疗可减少肿瘤负荷并提高生存。
要点
- 自体TIL/tumor共培养可诱导HLA依赖性IFNγ产生和T细胞活化,并上调肿瘤PD-L1表达。
- 抗PD-1抗体在CCNE1扩增模型中增加自体TIL介导的肿瘤溶解。
- 自体肿瘤反应性TIL联合抗PD-1治疗在PDX模型中减少肿瘤负荷并提高生存。
核心结论
- 本研究验证了一种新的、临床相关的体内测试卵巢癌免疫调节治疗策略的模型系统,并提供了评估患者特异性T细胞对免疫治疗反应的独特平台。
研究设计与样本
- 从三名患者供体建立原位高级别浆液性卵巢癌PDX模型,并通过免疫组化进行分子和组织学验证。
- 使用快速扩增方案从供体肿瘤扩增TIL,并进行离体TIL与肿瘤共培养以验证TIL对患者匹配自体肿瘤细胞的反应性。
- 通过流式细胞术和ELISA定量TIL活化标志物表达和细胞因子分泌。
- 作为概念验证,在自体TIL/肿瘤HGSOC PDX模型中测试抗PD-1单药治疗的疗效。
主要发现
- 自体TIL/肿瘤共培养中T细胞活化评估导致HLA依赖性IFNγ产生和T细胞活化增加。
- 响应增加的IFNγ产生,肿瘤细胞PD-L1表达增加。
- 在CCNE1扩增模型中,向TIL/肿瘤共培养中添加抗PD-1抗体增加自体肿瘤溶解。
- 来自平行患者匹配肿瘤的原位HGSOC PDX模型保持其原始形态和分子标志物谱。
- 在患者匹配PDX模型中,自体肿瘤反应性TIL给药联合抗PD-1治疗组肿瘤负荷减少且生存增加。
关键数值与推荐
- 共培养中HLA依赖性IFNγ产生和T细胞活化增加。
- 肿瘤细胞PD-L1表达随IFNγ产生增加而增加。
- 抗PD-1抗体在CCNE1扩增模型中增加自体肿瘤溶解。
- 自体肿瘤反应性TIL联合抗PD-1治疗组肿瘤负荷减少、生存增加。
临床怎么用
- 该平台可用于卵巢癌免疫调节治疗策略的体内测试。
- 该平台可用于评估患者特异性T细胞对免疫治疗的反应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to "humanize" ovarian cancer patient-derived xenograft (PDX) models by autologous transfer of patient-matched tumor infiltrating lymphocytes (TILs) to evaluate immunotherapies. METHODS: Orthotopic high-grade serous ovarian cancer (HGSOC) PDX models were established from three patient donors. Models were molecularly and histologically validated by immunohistochemistry. TILs were expanded from donor tumors using a rapid expansion protocol. Ex vivo TIL and tumor co-cultures were performed to validate TIL reactivity against patient-matched autologous tumor cells. Expression of TIL activation markers and cytokine secretion was quantitated by flow cytometry and ELISA. As proof of concept, the efficacy of anti-PD-1 monotherapy was tested in autologous TIL/tumor HGSOC PDX models. RESULTS: Evaluation of T-cell activation in autologous TIL/tumor co-cultures resulted in an increase in HLA-dependent IFNγ production and T-cell activation. In response to increased IFNγ production, tumor cell expression of PD-L1 was increased. Addition of anti-PD-1 antibody to TIL/tumor co-cultures increased autologous tumor lysis in a CCNE1 amplified model. Orthotopic HGSOC PDX models from parallel patient-matched tumors maintained their original morphology and molecular marker profile. Autologous tumor-reactive TIL administration in patient-matched PDX models resulted in reduced tumor burden and increased survival, in groups that also received anti-PD-1 therapy. CONCLUSIONS: This study validates a novel, clinically relevant model system for in vivo testing of immunomodulating therapeutic strategies for ovarian cancer, and provides a unique platform for assessing patient-specific T-cell response to immunotherapy.
引用
- Gitto SB, Kim H, Rafail S, et al. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. Gynecol Oncol. 2019. PMID: 31818495. doi:10.1016/j.ygyno.2019.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。